AHRMM Comment Letter to FDA Regarding the Draft Guidance for Industry on the Global Unique Device Identification Database (GUDID)

By AHRMM

On November 21, 2013, AHRMM submitted electronically

to the Division of Dockets Management (HFA-305), Food and Drug Administration, Department of Health and Human Services, regarding the 

on the global unique device identification database (GUDID), which was issued on September 24, 2013.

 
In the comment letter, AHRMM supports all of the outlined attributes identified for the GUDID system; however, AHRMM’s comments pertain to three specific GUDID attributes that we strongly recommended be included in the GUDID database requirements In AHRMM’s November 6, 2012, response to the UDI proposed rule:

  • Labeled as hazardous: End-users should always be aware of devices that may pose hazards in order to ensure safe handling as well as product integrity.
  • Contains radioactive isotopes (e.g., radioactive element and atomic number) This information is important for environmentally-safe disposal and end-user handling.
  • Has Safety Data Sheet (SDS) This information provides end-users with a reliable and readily-available source of information should an urgent need arise.

These three attributes no longer appear in the Draft Guidance Document. AHRMM reiterates that the above attributes should be added to the database requirements. These attributes provide critical information that can be the difference between whether a device contributes to or detracts from quality patient care.

Related Resources

On-Demand Educational Webinars
In the first half of the webinar, we will explore the Hospital PMI™, an ISM®<
White Papers
Explore your organization’s clinical integration maturity and leverage leadership involvement to make data-driven decisions.
Letter/Comment
In September 2019, FDA announced its
Press Releases
CHICAGO, July 23, 2020 — In partnership with the Association for Health Care Resource & Materials Management (AHRMM) of the American Hospital A
On-Demand Educational Webinars
Provider panelists discuss their post-pandemic approach to their business continuity programs, working with non-traditional buyers, diversifying…